Cargando…

Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial

BACKGROUND: Chronic anal fissure (CAF) is a painful condition that is unlikely to resolve with conventional conservative management. Previous studies have reported that topical treatment of CAF with glyceryl trinitrate (GTN) reduces pain and promotes healing, but optimal treatment duration is unknow...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliardi, G., Pascariello, A., Altomare, D. F., Arcanà, F., Cafaro, D., La Torre, F., De Nardi, P., Basso, L., De Stefano, I., Greco, V. J., Vasapollo, L., Amato, A., Pulvirenti D’Urso, A., Aiello, D., Bove, A.
Formato: Texto
Lenguaje:English
Publicado: Springer Milan 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924966/
https://www.ncbi.nlm.nih.gov/pubmed/20632059
http://dx.doi.org/10.1007/s10151-010-0604-1
_version_ 1782185640038760448
author Gagliardi, G.
Pascariello, A.
Altomare, D. F.
Arcanà, F.
Cafaro, D.
La Torre, F.
De Nardi, P.
Basso, L.
De Stefano, I.
Greco, V. J.
Vasapollo, L.
Amato, A.
Pulvirenti D’Urso, A.
Aiello, D.
Bove, A.
author_facet Gagliardi, G.
Pascariello, A.
Altomare, D. F.
Arcanà, F.
Cafaro, D.
La Torre, F.
De Nardi, P.
Basso, L.
De Stefano, I.
Greco, V. J.
Vasapollo, L.
Amato, A.
Pulvirenti D’Urso, A.
Aiello, D.
Bove, A.
author_sort Gagliardi, G.
collection PubMed
description BACKGROUND: Chronic anal fissure (CAF) is a painful condition that is unlikely to resolve with conventional conservative management. Previous studies have reported that topical treatment of CAF with glyceryl trinitrate (GTN) reduces pain and promotes healing, but optimal treatment duration is unknown. METHODS: To assess the effect of different treatment durations on CAF, we designed a prospective randomized trial comparing 40 versus 80 days with twice daily topical 0.4% GTN treatment (Rectogesic(®), Prostrakan Group). Chronicity was defined by the presence of both morphological (fibrosis, skin tag, exposed sphincter, hypertrophied anal papilla) and time criteria (symptoms present for more than 2 months or pain of less duration but similar episodes in the past). A gravity score (1 = no visible sphincter; 2 = visible sphincter; 3 = visible sphincter and fibrosis) was used at baseline. Fissure healing, the primary endpoint of the study, maximum pain at defecation measured with VAS and maximum anal resting pressure were assessed at baseline and at 14, 28, 40 and 80 days. Data was gathered at the end of the assigned treatment. RESULTS: Of 188 patients with chronic fissure, 96 were randomized to the 40-day group and 92 to the 80-day group. Patients were well matched for sex, age, VAS and fissure score. There were 34 (19%) patients who did not complete treatment, 18 (10%) because of side effects. Of 154 patients who completed treatment, 90 (58%) had their fissures healed and 105 (68%) were pain free. There was no difference in healing or symptoms between the 40- and the 80-day group. There was no predictor of fissure healing. A low fissure gravity score correlated with increased resolution of pain (P < 0.05) and improvement of VAS score (P < 0.05) on both univariate and multivariate analysis. A lower baseline resting pressure was associated with better pain resolution on univariate analysis (P < 0.01). VAS at defecation and fissure healing significantly improved until 40 days (P < 0.001), while the difference between 40 and 80 days was not significant. CONCLUSION: We found no benefits in treating CAF with topical GTN for 80 days compared to 40 days. Fissure healing and VAS improvement continue until 6 weeks of treatment but are unlikely thereafter.
format Text
id pubmed-2924966
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-29249662010-09-10 Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial Gagliardi, G. Pascariello, A. Altomare, D. F. Arcanà, F. Cafaro, D. La Torre, F. De Nardi, P. Basso, L. De Stefano, I. Greco, V. J. Vasapollo, L. Amato, A. Pulvirenti D’Urso, A. Aiello, D. Bove, A. Tech Coloproctol Original Article BACKGROUND: Chronic anal fissure (CAF) is a painful condition that is unlikely to resolve with conventional conservative management. Previous studies have reported that topical treatment of CAF with glyceryl trinitrate (GTN) reduces pain and promotes healing, but optimal treatment duration is unknown. METHODS: To assess the effect of different treatment durations on CAF, we designed a prospective randomized trial comparing 40 versus 80 days with twice daily topical 0.4% GTN treatment (Rectogesic(®), Prostrakan Group). Chronicity was defined by the presence of both morphological (fibrosis, skin tag, exposed sphincter, hypertrophied anal papilla) and time criteria (symptoms present for more than 2 months or pain of less duration but similar episodes in the past). A gravity score (1 = no visible sphincter; 2 = visible sphincter; 3 = visible sphincter and fibrosis) was used at baseline. Fissure healing, the primary endpoint of the study, maximum pain at defecation measured with VAS and maximum anal resting pressure were assessed at baseline and at 14, 28, 40 and 80 days. Data was gathered at the end of the assigned treatment. RESULTS: Of 188 patients with chronic fissure, 96 were randomized to the 40-day group and 92 to the 80-day group. Patients were well matched for sex, age, VAS and fissure score. There were 34 (19%) patients who did not complete treatment, 18 (10%) because of side effects. Of 154 patients who completed treatment, 90 (58%) had their fissures healed and 105 (68%) were pain free. There was no difference in healing or symptoms between the 40- and the 80-day group. There was no predictor of fissure healing. A low fissure gravity score correlated with increased resolution of pain (P < 0.05) and improvement of VAS score (P < 0.05) on both univariate and multivariate analysis. A lower baseline resting pressure was associated with better pain resolution on univariate analysis (P < 0.01). VAS at defecation and fissure healing significantly improved until 40 days (P < 0.001), while the difference between 40 and 80 days was not significant. CONCLUSION: We found no benefits in treating CAF with topical GTN for 80 days compared to 40 days. Fissure healing and VAS improvement continue until 6 weeks of treatment but are unlikely thereafter. Springer Milan 2010-07-15 2010-09 /pmc/articles/PMC2924966/ /pubmed/20632059 http://dx.doi.org/10.1007/s10151-010-0604-1 Text en © Springer-Verlag 2010
spellingShingle Original Article
Gagliardi, G.
Pascariello, A.
Altomare, D. F.
Arcanà, F.
Cafaro, D.
La Torre, F.
De Nardi, P.
Basso, L.
De Stefano, I.
Greco, V. J.
Vasapollo, L.
Amato, A.
Pulvirenti D’Urso, A.
Aiello, D.
Bove, A.
Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
title Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
title_full Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
title_fullStr Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
title_full_unstemmed Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
title_short Optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
title_sort optimal treatment duration of glyceryl trinitrate for chronic anal fissure: results of a prospective randomized multicenter trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924966/
https://www.ncbi.nlm.nih.gov/pubmed/20632059
http://dx.doi.org/10.1007/s10151-010-0604-1
work_keys_str_mv AT gagliardig optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT pascarielloa optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT altomaredf optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT arcanaf optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT cafarod optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT latorref optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT denardip optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT bassol optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT destefanoi optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT grecovj optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT vasapollol optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT amatoa optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT pulvirentidursoa optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT aiellod optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial
AT bovea optimaltreatmentdurationofglyceryltrinitrateforchronicanalfissureresultsofaprospectiverandomizedmulticentertrial